Anavex Life Sciences Corp (AVXL)

[WolfofMia]

These concerns have been discussed before.

There are many ways to reprice the drug once approved for AD.

Our pricing scheme might change from rare diseases schemes of high tags do to low volume of patients.

To a lower tags at a much much higher volume of patients with AD, PDD, Autism approval etc.

By then we will charge less and make way more on the volume itself, but first we price it for the indication we are getting approved.

Unless this miraculous PA for AD happens in Australia, the order of approval should be Rett-adults, Rett-kids, AD/PDD/PD/etc